U-M Health to purchase Edison platform for histotripsy, following FDA approval
HistoSonics, Inc. on LinkedIn: #histosonics #histotripsy #meetedison
U-M Health to purchase Edison platform for histotripsy, following FDA approval
Histotripsy receives FDA approval for treatment of liver tumors:
FDA Approval October 9th, 2023:
FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System | Business Wir.
.
Histotripsy liver cancer clinical trial: #HOPE4LIVER trial:
https://clinicaltrials.gov/ct2/show/NCT04572633?term=HistoSonics&draw=2&rank=1
Histotripsy renal cancer clinical trial: #CAIN trial:
https://www.clinicaltrials.gov/study/NCT05432232?term=CAIN&rank=1
Department of Radiology – Basic Radiological Science Division (BRS)
If you are a liver cancer patient seeking histotripsy treatment at the University of Michigan hospital, please contact Dr. Mishal Mendiratta-Lala at mmendira@med.umich.edu.
If you are a liver cancer patient seeking histotripsy treatment outside Michigan, please contact Dr. Joe Amaral at joseph.amaral@histosonics.com.
If you are a renal cancer patient interested in participating in a histotripsy clinical trial, please contact Dr. Joe Amaral at joseph.amaral@histosonics.com.
If you are seeking veterinarian histotripsy treatments for your pets, please contact Mindy Quigley at Virginia Tech Clinical Research Office: vettrials@vt.edu.
Currently, there are no clinical trials or clinical treatments available for human patients with diseases other than liver cancer and renal cancer. We are working hard to push for clinical histotripsy treatments of other diseases.